Related Experiment Video
Updated: Aug 6, 2026
Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
Published on: June 28, 2018
The Favorable Short-Term Efficacy of Preexisting COPD for Extensive-Stage Small-Cell Lung Cancer Receiving
Ya Chen1, Hongyu Liu2, Junqiang Zhang1
1Division of Life Science and Medicine, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Background:
Preexisting chronic obstructive pulmonary disease (COPD) is associated with favorable clinical efficacy in NSCLC patients undergoing immune checkpoint inhibitors (ICIs). But the impact of COPD comorbidities on SCLC patients that are receiving immunotherapy remains unclear.
Methods:
Patients with extensive-stage SCLC (ES-SCLC) received carboplatin combined with etoposide (carboplatin-etoposide, EC group) or durvalumab plus carboplatin-etoposide (EC + PD-L1 group) treatment as first line therapy were collected. In EC + PD-L1 group, survival of patients with preexisting COPD and patients without preexisting COPD were further compared.
Results:
A total of 120 ES-SCLC patients who met the eligibility criteria were included in this study. The median overall survival (OS) and the progression-free survival (PFS) were significantly longer in the EC + PD-L1 group than in the EC group, with a HR of 0.37 (95% CI, 0.16-0.88; p = 0.001) and 0.42 (95% CI, 0.23-0.77; p < 0.001), respectively. We further stratified groups by COPD status in EC + PD-L1 group and EC group. In EC + PD-L1 group, PFS was significantly prolonged in COPD group compared with the non-COPD group, with a HR of 0.57 (95% CI, 0.35-0.96; p = 0.018). The COPD group demonstrated a numerically higher objective response rate than the non-COPD group, though the difference was not statistically significant (p = 0.292). No OS benefit was found between the groups.
Conclusion:
Preexisting COPD status may be associated with favorable clinical efficacy in ES-SCLC patients undergoing ICIs.
